Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of AMG 386 with paclitaxel ± bevacizumab in HER2‑negative metastatic or locally recurrent breast cancer
2007-003384-51Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of trebananib in breast cancer (4 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Aug 2007; status: completed.
02
Drugs
trebananib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003384-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003384-51.